BridgeBio Pharma, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
William Blair reiterated an Outperform rating on BridgeBio Pharma (BBIO), citing three upcoming product launches and $4B in de-risked peak sales. The firm highlights BBIO's revenue growth of 202% and 94% gross margins, believing shares are undervalued. Recent analyst reviews, including from H.C. Wainwright and Jefferies, also reiterated Buy ratings with price targets up to $120.
BridgeBio's oral treatment for achondroplasia received FDA priority review, with a decision expected by Feb. 4, 2027. Shionogi acquired IntraBio for $2 billion. Arrivent Biopharma's lung cancer treatment failed in a Phase 3 study. The Trump administration plans to develop a system for insurers to disclose drug prices by May 2024.
BridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning BBIO (BridgeBio Pharma, Inc.). Coverage has skewed bullish: 14 bullish, 0 neutral, and 0 bearish.
Recent BBIO coverage spans financial news and insider activity.
In the last 30 days, BBIO insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($691K). The most active reporter was Kumar Neil, Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst reiteration may boost investor confidence and support price appreciation.
Potential upside if approval is granted; downside risk if delayed or denied.
Positive regulatory milestone likely to boost BBIO share price as approval prospects improve.
Positive Phase III data and upgraded price targets are likely to lift BBIO shares as investors price in higher peak‑sales potential.
Positive Phase 2 data and analyst endorsement suggest upward price pressure.
AlphAI scores every news story that mentions BBIO with an AI model for sentiment and relevance, and aggregates insider trades from BridgeBio Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
William Blair reiterated an Outperform rating on BridgeBio Pharma (BBIO), citing three upcoming product launches and $4B in de-risked peak sales. The firm highlights BBIO's revenue growth of 202% and 94% gross margins, believing shares are undervalued. Recent analyst reviews, including from H.C. Wainwright and Jefferies, also reiterated Buy ratings with price targets up to $120.
1 min readBridgeBio's oral treatment for achondroplasia received FDA priority review, with a decision expected by Feb. 4, 2027. Shionogi acquired IntraBio for $2 billion. Arrivent Biopharma's lung cancer treatment failed in a Phase 3 study. The Trump administration plans to develop a system for insurers to disclose drug prices by May 2024.
2 min readBridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.
3 min readJefferies maintained a Buy rating on BridgeBio Pharma (BBIO) with a $110 target, citing positive Phase III data for BBP-418. The stock trades at $66.46, with a consensus Strong Buy rating. Jefferies expects over $1 billion in peak sales and a 94% gross profit margin. Other analysts also reiterated Buy ratings with targets up to $120. BBIO's revenue surged 202% in the last year.
2 min readTD Cowen reiterated a Buy rating and $110 price target on BridgeBio Pharma (BBIO) after positive cardiac data for BBP-418. The therapy showed improvements in biomarkers and stabilization in cardiac function. BBIO has a consensus Strong Buy rating and expects FDA approval by November 27. Analysts project BBP-418 could generate over $1 billion in sales. BBIO's revenue grew over 200% in the last year with 94% gross margins. Several analysts have raised price targets and maintained positive ratings.
2 min readBridgeBio Pharma (BBIO) reported positive Phase 3 trial data for BBP-418, showing biomarker improvements in LGMD2I/R9 patients. The FDA granted Priority Review with a PDUFA date of November 27, 2026. BBIO stock is down 2.30%, trading at $65.70.
2 min readCantor Fitzgerald maintained an Overweight rating on BridgeBio Pharma (BBIO) with a $110 price target, noting a 28% decline from its 52-week high. The firm cited competitive threats and quarterly result uncertainties. BBIO reported Q2 2026 revenue of $243.7M, beating estimates. Several analysts raised price targets, citing positive clinical data and market dynamics. KKR Genetic Disorder L.P. plans a secondary offering of 5M BBIO shares.
1 min readBridgeBio (BBIO) reported positive 12-month Phase 3 data for BBP-418 in LGMD2I/R9, showing significant improvements in cardiac biomarkers compared to placebo. The drug is under FDA Priority Review with a PDUFA date of Nov. 27, 2026.
2 min readBridgeBio Pharma (BBIO) presented positive 12-month data from its Phase 3 FORTIFY trial of BBP-418 for LGMD2I/R9. 100% of treated patients with elevated HS troponin I normalized levels vs. 40% on placebo. 54% of treated patients had stable or improved LVEF vs. 25% on placebo. BBP-418 also increased glycosylated αDG to asymptomatic levels. The FDA has a PDUFA target action date of November 27, 2026.
3 min readKumar Neil (Chief Executive Officer) sold 10,000 indirectly-held shares of BridgeBio Pharma, Inc. (BBIO) at an average of $69.08 ($69.01–$69.57, $0.69M total) across 2 trades on 2026-09-17 under a Rule 10b5-1 trading plan.
1 min read
